BRIEF published on 04/22/2026 at 22:05, 8 days 5 hours ago Inventiva strengthens its leadership for phase 3 of lanifibranor Appointment Biopharmaceutical Direction Phase 3 Lanifibranor
BRIEF published on 04/22/2026 at 22:05, 8 days 5 hours ago Inventiva Bolsters Executive Team as It Nears Key Phase 3 Data Milestone Phase 3 Trial Lanifibranor Leadership Expansion MASH Treatment Inventiva Biopharmaceutical
PRESS RELEASE published on 04/22/2026 at 22:00, 8 days 5 hours ago Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor Inventiva strengthens leadership team with new key hires for lanifibranor Phase 3 data readout, bolstering expertise in finance, legal, and HR to drive growth and commercialization Growth Leadership Team Phase 3 Inventiva Lanifibranor
BRIEF published on 04/08/2026 at 22:05, 22 days 5 hours ago Inventiva Submits 2025 Financial Reports to AMF and SEC Inventiva 2025 Financial Reports MASH Treatments Biopharmaceutical Developments AMF And SEC Filings
BRIEF published on 04/08/2026 at 22:05, 22 days 5 hours ago Inventiva files its Universal Registration Document and its 2025 Annual Report Annual Report Biopharmaceutical Registration Document Inventiva MASH
PRESS RELEASE published on 04/08/2026 at 22:00, 22 days 5 hours ago Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F Inventiva files 2025 Universal Registration Document and Annual Report on Form 20-F with AMF and SEC, focusing on MASH therapies Biopharmaceutical 2025 Filing Inventiva MASH
BRIEF published on 04/02/2026 at 15:55, 28 days 11 hours ago JP Morgan Chase & Co. crosses the thresholds for participation in INVENTIVA Voting Rights Threshold Crossing JP Morgan Inventiva Equity Swap
BRIEF published on 03/30/2026 at 22:16, 1 month 1 day ago Inventiva Announces 2025 Financial Results and Business Update Public Offering Cash Reserves Inventiva Lanifibranor 2025 Financial Results
PRESS RELEASE published on 03/30/2026 at 22:11, 1 month 1 day ago Inventiva reports 2025 full year results and provides a business update Inventiva reports 2025 full year results with €4.5 million revenues, provides business update on strategic pipeline, clinical trials, and financial performance Financial Performance Business Update Clinical Trials Inventiva 2025 Results
BRIEF published on 03/23/2026 at 22:05, 1 month 8 days ago Inventiva Announces Schedule for 2025 Financial Results Financial Results Conference Call Biopharmaceutical Inventiva MASH
Published on 05/01/2026 at 02:55, 13 minutes ago GLG Life Tech Corporation Reports 2025 Annual & Fourth Quarter Financial Results
Published on 05/01/2026 at 01:00, 2 hours 8 minutes ago PPX Mining Announces Grant of Stock Options, Restricted Share Units and Deferred Share Units
Published on 05/01/2026 at 00:45, 2 hours 23 minutes ago Inventus Announces Closing of $2.5 Million Non-Brokered Flow-Through Financing
Published on 04/30/2026 at 23:55, 3 hours 13 minutes ago Pinetree Capital Announces Unaudited Financial Results for the Period Ended March 31, 2026
Published on 04/30/2026 at 23:05, 4 hours 3 minutes ago AIP Realty Trust Announces Year End 2025 Results
Published on 04/30/2026 at 23:39, 3 hours 29 minutes ago Anemoi International Ltd: Final Results For Year Ended 31 December 2025
Published on 04/30/2026 at 22:35, 4 hours 33 minutes ago Curaleaf Completes Buyout of Remaining Stake in Germany's Four 20 Pharma
Published on 04/30/2026 at 22:04, 5 hours 4 minutes ago Interim individual financial statements for the period ending on March 31, 2026 of Sirma Group Holding JSC
Published on 04/30/2026 at 19:00, 8 hours 7 minutes ago DOUGLAS Group grows sales in Q2 and updates full-year guidance on adjusted EBITDA
Published on 04/30/2026 at 19:00, 8 hours 8 minutes ago BioVersys announces approval of all Board Proposals at Annual General Meeting of Shareholders
Published on 04/30/2026 at 20:00, 7 hours 7 minutes ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 7 hours 52 minutes ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 8 hours 8 minutes ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 8 hours 58 minutes ago Minutes of the Combined General Meeting held on April 30, 2026
